Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study

• Tipo: Artigo em Revista Científica Internacional
• Data: 2022

Autores

Torres, T (Autor) Outra; Paiva Lopes, MJ (Autor) Outra; Goncalo, M (Autor) Outra; Claro, C (Autor) Outra; Oliveira, M (Autor) Outra; Gomes, J (Autor) Outra; Vieira, AP (Autor) Outra; Amoedo, P (Autor) Outra; Alpalhao, M (Autor) Outra; Nogueira, M (Autor) Outra; Santiago, F (Autor) Outra; Henrique, M (Autor) Outra; Amaro, C (Autor) Outra; Esteves, T (Autor) Outra; Alves, J (Autor) Outra; Cerejeira, D (Autor) Outra; Mendes Bastos, P (Autor) Outra; Pestana, M (Autor) Outra; Ramos, L (Autor) Outra; Rocha, J (Autor) Outra; Carvalho, R (Autor) Outra; Teixeira, L (Autor) ICBAS; Selores, M (Autor) Outra; Mota, A (Autor) Outra; Filipe, P (Autor) Outra

Revista

Título: Journal of Dermatological Treatment

Vol. 33

Páginas: 2554-2559

ISSN: 0954-6634

Editora: Taylor & Francis

Indexação

ISI Web of Knowledge - 5 Citações

Scopus - 5 Citações

Outras Informações

ID Authenticus: P-00W-2QR

DOI: 10.1080/09546634.2022.2035309

Abstract (EN): Introduction Atopic dermatitis (AD) is a difficult-to-treat inflammatory skin disease with a high impact on patients' quality of life. Dupilumab, an IL-4 and IL-13 inhibitor, was the first monoclonal antibody approved for the treatment of moderate-to-severe AD and is currently approved in patients aged 6 or older. Methods This is a nationwide, multicenter, retrospective, 48-week study designed by the Portuguese Group of AD to assess real-world efficacy and safety of dupilumab for the treatment of AD. Results A total of 169 patients were enrolled, with a mean disease duration of 22.75 (+/- 11.98) years. The percentage of patients achieving an improvement of at least 75% in Eczema Area and Severity Index (EASI) compared to baseline (EASI75 response) at weeks 12 and 48 was 67.6% and 74.1%, respectively. In the same timepoints, 25.0% and 44.1% achieved an EASI90 response. Patient-reported outcome measures also improved throughout the study period. Regarding safety, 32.0% of the patients developed adverse events, with conjunctivitis (26.6%), persistent facial erythema (4.7%), and arthritis/arthralgia (3.6%) as the more frequently reported. Conclusion Data from real-world populations are crucial to guide clinicians in their daily decisions. This study provides data demonstrating that dupilumab is an effective and safe therapeutic option for AD.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 6